16 October 2019
Visiongain has launched a new pharma report ‘’Muscle Stimulator Market Report 2020-2030’’ by Product (Burst Mode Alternating Current, Functional Electrical Stimulation, Interferential, Microcurrent Electrical Neuromuscular Stimulator, Neuromuscular Electrical Stimulation, Transcutaneous Electrical Nerve Stimulation, Other Products), Modality (Handheld Devices, Portable Devices, Table-Top Devices), Application (Musculoskeletal Disorders, Neurological Disorders, Pain Management, Other Disorders), End User (Ambulatory Surgical Centers, Hospitals, Physiotherapy Clinics, Homecare, Sports Clinics), and Geography.
The global Muscle Stimulator market is anticipated to grow at a lucrative CAGR of 5.1% and anticipated to surpass USD 1.1 Billion by 2030.
The introduction of technologically advanced wearable muscle stimulation devices is anticipated to fuel the growth of muscle simulator marker over the forecast period. Also, growing research activities leading to breakthrough technologies are in the process of opening up new avenues for market growth. SmartMio is Smartmissimo's first wearable muscle stimulator which was launched in the year 2014. This device can connect to a smartphone via Bluetooth and provide small doses of electrical stimulation that can improve exercise which is primarily used by athletes.
Physiotherapists are increasingly shifting their preference from manual techniques to muscle stimulation devices, such as galvanic electrical stimulation and transcutaneous electrical nerve stimulation (TENS) to treat patients in clinical or home care settings.
Anterior cruciate ligament (ACL) tear, hamstring strains, and hip flexor strains are among the most prevalent sports injuries that require muscle stimulation treatment. With the growing incidence of these muscle injuries among sportsmen, it is anticipated to fuel growth over the forecast period.
Also, musculoskeletal disorders are one of the main causes of physical disability in several developed countries. According to 2017 statistics of the Arthritis Research U.K., over 30% of individuals in the United Kingdom are affected by musculoskeletal disorders. Such factors are projected to support market growth in the European region.
High costs of the muscle stimulator products, particularly in emerging markets, may hinder the growth of the muscle stimulator industry. In addition to this, there is stringent government regulation on the use of such instruments even in the developed markets of North America and Europe. There are instances where the use of such devices has led to shocks and burns without the supervision of medical experts. Consequently, it is becoming increasingly hard to obtain permission to introduce fresh versions in the market owing to rigid government regulations.
North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of the increasing adoption of advanced technologies and innovative medical devices. Favorable economic conditions, growing healthcare expenditure, growing living standards, and growing focus on delivering quality medical services are some of the factors that are propelling muscle simulator market growth.
Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to advancement in technology, rising adoption of muscle stimulators and increasing sports injuries.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global muscle simulator market. Companies are also increasing their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the market.
The comprehensive market report features companies such as Beurer GmbH, BioMedical Life Systems, Inc., DJO Global Inc., EMS Physio Ltd., NeuroMetrix Inc., OG Wellness Technologies Co., Ltd., Omron Corporation, RS Medical Inc., Zimmer MedizinSysteme GmbH, and Zynex Inc. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.